Evaluation of Safety/Efficacy of Diagnostic Skin Test Panel and Desensitization Hormone Kit for Treatment of Premenstrual Syndrome (PMS)

Official Title: “A Phase II Randomized, Two-arms, Single-blind, Cross Controlled Study for Evaluation the Safety and Efficacy of Diagnosis and Treatment of Premenstrual Syndrome by Detecting Skin Reactions Followed by Desensitization to Sex Hormones”

The EVE-PMS technology is intended for determination of intolerance or sensitivity to sex hormones, among women suffering from severe PreMenstrual Syndrome (PMS) and desensitizes them with the relevant sex hormones in order to reduce PMS symptoms.

The system includes skin testing panel for identification of hormones to which the patients might be sensitive. Tests are applied close to the ovulation period and the skin reaction is examined in 20 minutes, 48 hours and daily during the following month. Results of skin tests and patient's history will determine the eligibility of the patients to enter a desensitization protocol.

During the desensitization period hormones to which the patient were found sensitive to, are injected intradermally three times (once a month) within the luteal phase in increasing doses. The end-point of the study is a statistically significant decrease, or elimination of PMS symptoms, compared to a solvent group.

Intervention(s) in this Clinical Trial

• Drug: Skin test panel and desensitization kit
  • Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators. Hormones: Progesterone 1mmol/L; Estradiol 1mmol/L; Estrone 3mmol/L; Estriol 3mmol/L Controls: Saline (NaCl) 0.9%; Ethyl Oleate with 10% Benzyl Alcohol; Histamine phosphate 1mg/ml (epicutaneous- prick test) Patients with positive skin test to at least one sex hormone will be injected with an increasing volume of the appropriate hormone at the same concentration as it was used in the skin test as follows: Week 4th of the study (luteal phase of 2nd menstrual cycle) - 0.04 ml Week 8th of the study (luteal phase of 3rd menstrual cycle) - 0.08 ml Week 12th of the study (luteal phase of 4th menstrual cycle) - 0.16 ml
• Drug: Skin test panel and solvent
  • Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators. Hormones: Progesterone 1mmol/L; Estradiol 1mmol/L; Estrone 3mmol/L; Estriol 3mmol/L Controls: Saline (NaCl) 0.9%; Ethyl Oleate with 10% Benzyl Alcohol; Histamine phosphate 1mg/ml (epicutaneous- prick test) Patients with positive skin test to at least one sex hormone will be injected with an increasing volume of the solvent as follows: Week 4th of the study (luteal phase of 2nd menstrual cycle) - 0.04 ml Week 8th of the study (luteal phase of 3rd menstrual cycle) - 0.08 ml Week 12th of the study (luteal phase of 4th menstrual cycle) - 0.16 ml

Arms, Groups and Cohorts in this Clinical Trial

• Active Comparator: Hormones
• Placebo Comparator: Solvent

Primary Measures

• To assess the efficacy of hormonal desensitization compared to solvent treatment in reduction of the PMS symptoms severity and length of PMS by subjects with severe PMS symptoms (according to criteria of PMS).
  • Time Frame: 5-6 months
    Safety Issue?: Yes

Secondary Measures

• To assess the efficacy of hormonal desensitization compared to solvent treatment in reduction of the breast swelling and tenderness in 4 weeks of treatment.
  • Time Frame: 2-3 months
    Safety Issue?: Yes

Inclusion Criteria:

• 1. Person is over the age of 20 but not older than age 45.
• 2. Person is willing to participate as evidenced by signing the written informed consent form.
• 3. Suffers from known dominant severe symptom of breast swelling and tenderness (level 7-10 according to standard scale of PMS symptoms severity)
• 4. Other severe symptoms of Premenstrual syndrome (based on WHO and ACOG criteria). This may include one or more of PMS symptoms with level 7-10 according to standard scale of PMS symptoms severity.
• 5. At work, school, home, or in daily routine, at least one of the PMS symptoms caused reduction of productivity or inefficiency
• 6. At least one of the PMS symptoms caused avoidance of or less participation in hobbies or social activities
• 7. At least one of the PMS symptoms interfere with relationships with others
• Timing of PMS symptom(s): during the 14 days prior to onset of menstrual flow (rather than spotting) and up to 5 days during the menstrual flow.
• Pattern and length of PMS symptomatic period: minimum of 2 days, up to 14 days.
• For PMS diagnosis two out of last three consecutive menstrual cycles were monitored by daily monitoring of symptoms.
• Timing and length of asymptomatic phase: day 6 to at least day 10 of the menstrual cycle.
• Cyclicity - presentation of the 'off-on' phenomenon: there should be a clear shift from no PMS symptoms to PMS symptoms.
• Reliable non hormonal contraception.

Exclusion Criteria:

• 1. Pregnant or lactating woman
• 2. Oral contraceptives during last three months, including hormonal IUD (trade name mirena).
• 3. Serious health problems.
• 4. Unexplained menstrual disorders.
• 5. Treated by hormones (estrogen and progesterone).

Gender Eligibility for this Clinical Trial: Female

Minimum Age for this Clinical Trial: 20 Years

Maximum Age for this Clinical Trial: 45 Years

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Lead Investigator: EVE Medical Systems Ltd. Industry

Overall Clinical Trial Officials and Contacts

Shmuel Kivity, Prof. Principal Investigator Tel Aviv Sourasky Medical Center, Department of Allergy and clinical immunology  

Overall Contact: Yonit Bomstein, Dr. +972-54-7889917 ybomstein@evepms.com

Information obtained from ClinicalTrials.gov on February 12, 2012

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00873262

Study ID Number: EVE-2008-03

ClinicalTrials.gov Identifier: NCT00873262

Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration